The Mexico specific pollen allergies market is witnessing significant growth due to the high prevalence of pollen allergies in the country. Increasing awareness about pollen allergies and improved allergy testing methods drive early diagnosis and treatment seeking. The adoption of allergen immunotherapy as an effective long-term solution enhances patient outcomes. Supportive government policies, rising healthcare expenditure, and development in healthcare infrastructure further boost market expansion. With a focus on tailored treatments for regional allergens and targeted awareness campaigns, Mexico aims to provide effective solutions and improve the quality of life for pollen allergy sufferers.
Access Full Report @ https://www.databridgemarketresearch.com/zh/reports/mexico-specific-pollen-allergies-market
Data Bridge Market Research analyses that the Mexico Specific Pollen Allergies Market is expected to grow at a CAGR of 6.5% during the forecast period of 2022 to 2029. Mexico has a high prevalence of pollen allergies due to its diverse climate and vegetation. This drives the demand for treatments and management solutions to address the allergy burden and improve the quality of life for affected individuals.
Key Findings of the Study
Increasing awareness is expected to drive the market's growth rate
As awareness about pollen allergies grows, more individuals become conscious of the potential health implications associated with these allergies. This increased awareness encourages people to recognize allergy symptoms and seek proper medical evaluation and treatment. Healthcare providers are also more attuned to identifying pollen allergies, leading to earlier diagnosis and personalized treatment plans. Ultimately, the emphasis on awareness empowers patients to take proactive measures in managing their allergies, improving overall health outcomes and quality of life.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014-2019)
|
|
Segments Covered
|
Drug Type (Antihistamines, Decongestants, Corticosteroids, Anticholinergics, and Others), Diagnostic Test (In Vivo Test and In Vitro Test), Product (Instruments, Reagents and Kits, and Others), End User (Hospitals, Diagnostics Laboratories, Academic and Research Institutes, and Others), Distribution Channel (Direct Tender and Retail Sales)
|
|
Market Players Covered
|
Siemens Healthcare GmbH (Germany), Sanofi (France), bioMérieux SA (France), GlaxoSmithKline plc. (U.K.), Minaris Medical America, Inc. (U.S.), Quest Diagnostics Incorporated (U.S.), Circassia (U.K.), Alcon Inc. (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Johnson & Johnson SA de CV (Mexico), Lincoln Diagnostics, Inc. (U.S.), EUROIMMUN Medizinische Labordiagnostika AG (Germany), Bayer Pharmaceuticals (Germany), Prestige Consumer Healthcare Inc. (U.S.), CINFA LABORATORIES (Spain), Perrigo Company plc. (Ireland)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The Mexico specific pollen allergies market is segmented on the basis of drug type, diagnosis test, product, end user, and distribution channel.
- On the basis of drug type, the market is segmented into antihistamines, corticosteroids, decongestants, anticholinergics, and others.
- On the basis of diagnostic test, the market is segmented into in vivo test and in vitro test.
- On the basis of product, the market is segmented into instruments, reagents, and kits, and others
- On the basis of end user, the market is segmented into hospitals, diagnostics laboratories, academic and research institutes, and others.
- On the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and others.
Major Players
Data Bridge Market Research recognizes the following companies as the major Mexico specific pollen allergies market players in Mexico specific pollen allergies market are Minaris Medical America, Inc. (U.S.), Quest Diagnostics Incorporated (U.S.), Circassia (U.K.), Alcon Inc. (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Johnson & Johnson SA de CV (Mexico), Lincoln Diagnostics, Inc. (U.S.)
Market Developments
- In 2022, Stallergenes Greer announced a research collaboration with Imperial College London to discover biomarkers of AIT efficacy.
- In 2022, BioMérieux and NecstGen collaborated to accelerate the development of Cell and Gene Therapies (CGT) through advanced testing technologies.
- In 2021, Prestige Consumer Healthcare announced that the company has completed the previously announced acquisition of TheraTears and other over-the-counter consumer brands. This is expected to increase the company’s manufacturing capacity in the U.S. and help in revenue generation.
- In 2021, EUROIMMUN Medizinische Labordiagnostika AG and Immunodiagnostic Systems (IDS) partnership to cooperate in the fields of research and development, production as well as distribution, and this will help to grow the business and generate revenue.
- In 2020, ALK-Abello launched a new sublingual allergy immunotherapy tablet for grass pollen allergies. The tablet is designed to be taken at home and provides patients with a more convenient treatment option
- In 2020, DBV Technologies announced that it had received FDA approval for its patch-based immunotherapy product for peanut allergies. The company is also developing treatments for other food allergies and is exploring the use of its technology for other types of allergies.
For more detailed information about the Mexico specific pollen allergies market report, click here – https://www.databridgemarketresearch.com/zh/reports/mexico-specific-pollen-allergies-market
